噻托溴铵联合布地奈德福莫特罗治疗ACOS的效果及对患者免疫功能、肺功能的影响

Effect of tiotropium combined with budesonide formoterol in the treatment of ACOS and its influences on immune function and lung function of patients

目的分析噻托溴铵联合布地奈德福莫特罗治疗哮喘-慢阻肺重叠综合征(ACOS)的效果及对患者免疫功能、肺功能的影响。方法选取2019年10月至2020年10月我院收治的60例ACOS患者作为研究对象,根据治疗方案的不同将其分为参照组(30例,布地奈德福莫特罗)和研究组(30例,噻托溴铵联合布地奈德福莫特罗)。比较两组的治疗效果。结果研究组的治疗总有效率为93.33%,明显高于参照组的73.33%(P<0.05)。治疗后,两组的白细胞分化抗原4阳性(CD4+)、白细胞分化抗原4阳性/白细胞分化抗原8阳性(CD4+/CD8+)均高于治疗前,白细胞分化抗原8阳性(CD8+)低于治疗前,且研究组优于参照组(P<0.05)。治疗后,两组的第1秒用力呼气容积(FEV1)、第1秒用力呼气容积与用力肺活量的比值(FEV1/FVC)、深吸气量/肺总量(IC/TLC)均高于治疗前,且研究组高于参照组(P<0.05)。治疗后,两组的健康调查简表(SF-36)各维度评分均高于治疗前,且研究组高于参照组(P<0.05)。研究组的不良反应总发生率为10.00%,略低于参照组的23.33%,但差异无统计学意义(P>0.05)。结论噻托溴铵联合布地奈德福莫特罗治疗ACOS的效果显著,可改善患者的免疫功能、肺功能,提升生活质量,安全性良好。

Objective To analyze the effect of tiotropium combined with budesonide formoterol in the treatment of asthma-chronic obstructive pulmonary disease overlap syndrome(ACOS)and its influences on immune function and lung function of patients.Methods A total of 60 patients with ACOS admitted in our hospital from October 2019 to October 2020 were selected as the research objects.According to different treatment options,the patients were divided into reference group(30 cases,budesonide formoterol)and study group(30 cases,tiotropium combined with budesonide formoterol).The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the study group was 93.33%,which was significantly higher than 73.33%in the reference group(P<0.05).After treatment,the cluster of differentiation 4 positive(CD4+)and cluster of differentiation 4 positive/cluster of differentiation 8 positive(CD4+/CD8+)in the two groups were higher than those before treatment,and cluster of differentiation 8 positive(CD8+)was lower than that before treatment,and those in the study group were better than the reference group(P<0.05).After treatment,the forced expiratory volume in one second(FEV1),forced expiratory volume in one second/forced vital capacity(FEV1/FVC)and inspiratory capacity/total lung capacity(IC/TLC)of the two groups were higher than those before treatment,and those in the study group were higher than the reference group(P<0.05).After treatment,the scores of each dimension of 36-Item Short-Form Health Survey(SF-36)in the two groups were higher than those before treatment,and those in the study group were higher than the reference group(P<0.05).The total incidence of adverse reactions in the study group was 10.00%,which was slightly lower than 23.33%in the reference group,but the difference was not statistically significant(P>0.05).Conclusion Tiotropium combined with budesonide formoterol in the treatment of ACOS has a significant effect,which can effectively improve the immune function,lung function and the quality of life of patients,and has good safety.